# Vitamin K2 (MK-7)

> Vitamin K2 in the MK-7 form activates the proteins that route calcium into bone rather than soft tissue and vasculature, and supports collagen matrix quality relevant to hEDS. It works synergistically with D3 to reduce the soft tissue calcification risk that long-term D3 supplementation can otherwise drive. ZebraThrive uses 100 mcg MK-7 daily.

**Page:** https://www.wellnessforzebras.com/ingredients/vitamin-k2
**Brand:** ZebraThrive
**Author:** Ken Chapman, Founder of ZebraThrive
**Last reviewed:** 2026-05-11
**Daily dose:** 100 mcg MK-7 daily
**Form used:** MK-7 (Menaquinone-7)
**Target population:** Adults 18+ with hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), or Mast Cell Activation Syndrome (MCAS).
**Regulatory framing:** US DSHEA dietary supplement. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

## Key benefits

- Reduces arterial calcification risk via Matrix Gla Protein activation
- Inhibits mast cell degranulation (Kimura studies)
- Reduces MMP-3 in clinical trials (collagen protective)
- Superior 72-hour half-life vs MK-4

## What it is

A fat-soluble vitamin that activates proteins essential for calcium regulation and vascular health

## Why we include it

Works synergistically with D3 to reduce the risk of soft tissue calcification, supports collagen matrix quality, and demonstrates mast cell stabilizing properties in lab models

## Plain-language summary

Vitamin K2 (specifically the MK-7 form, menaquinone-7) is the cofactor that activates the proteins responsible for directing calcium where it belongs - bones and teeth, not arteries or soft tissues. We include K2 alongside D3 because D3 increases calcium absorption, and K2 ensures that calcium ends up in the right places. For the triad, K2 also has documented mast cell stabilization (the 1975 Kimura studies showed K2 inhibited mast cell degranulation in both rat and human models) and supports bone density - relevant for the higher fracture rates seen in EDS populations. Important: K2 is contraindicated with warfarin.

## Mechanism

Vitamin K2 activates Matrix Gla Protein (MGP), which binds calcium in the bloodstream and limits its deposition in arteries and soft tissues, directing it toward bone instead. This is critical when taking D3, which increases calcium absorption.

In connective tissue, K2 activates osteocalcin, enhancing collagen matrix quality. Research shows it increases collagen synthesis via the SXR pathway and organizes collagen fibrils. Regarding mast cells, historical studies demonstrated that menaquinone significantly inhibits degranulation in both models and human basophils, with clinical effectiveness shown in asthma trials.

## Condition-specific notes

### MCAS (Mast Cell Activation Syndrome)

K2 appears to stabilize mast cells. However, fermentation sources (natto) can contain histamine. It is critical to use purified, pharmaceutical-grade MK-7 extracts that remove these contaminants. Some sensitive patients may prefer synthetic or chickpea-fermented alternatives.

### hEDS (hypermobile Ehlers-Danlos Syndrome)

Demonstrates MMP inhibition and supports collagen synthesis. While direct hEDS data is missing, the reduction in MMP-3 seen in other conditions is theoretically beneficial for preventing ECM degradation.

### POTS (Postural Orthostatic Tachycardia Syndrome)

This represents a large evidence gap. Improved arterial stiffness could theoretically benefit blood pressure regulation in POTS, but direct autonomic data is currently lacking.

## Why this form

**Selected form:** MK-7 (Menaquinone-7)

MK-7 is far superior to MK-4 due to its 72-hour half-life and 10x better bioavailability. 420 μg of MK-7 is easily detectable in serum while the same dose of MK-4 is not.

**Form comparison:**

| Form | Notes | Selected |
|---|---|---|
| MK-7 (Menaquinone-7) | 72-hour half-life; once-daily dosing; 10x better bioavailability | Yes |
| MK-4 (Menaquinone-4) | 6-hour half-life; requires multiple doses; poor absorption | No |
| Chickpea-fermented or synthetic MK-7 source | Soy-free, no natto-derived biogenic amines; descriptive of our sourcing | No |

## Dose protocol

| Step | Dosage | Notes |
|---|---|---|
| Weeks 1-2 | 50 mcg daily | Conservative start |
| Week 3+ | 100 mcg daily | Standard therapeutic dose |

**Timeline to effect:** Take with fat. Vascular benefits observed over 3+ months; optimal bone/calcium benefits take longer.

## Evidence summary

### Mast Cell Stabilization

Historical research demonstrates significant stabilizing properties.

- [1] **Kimura I et al..** Finding: Menaquinone significantly inhibited mast cell degranulation in rat models and human basophils.. PMID: 126001.
- [6] **Kimura I et al..** Design: Controlled trial, n=191 asthma patients. Finding: 72.7-90.9% clinical effectiveness in asthma compared to 16.7% for placebo.. PMID: 51576.

### MMP Inhibition (Collagen Protection)

Decreases MMP-3 levels, protecting the collagen matrix.

- [2] **Abdel-Rahman MS.** Design: RCT, n=84. Finding: 100 μg/day MK-7 significantly decreased MMP-3 and disease activity markers.. PMID: 26073022.

### Vascular Elasticity

Long-term trials demonstrate improved vascular elasticity and reduced stiffness.

- [3] **Knapen et al..** Design: 3-year RCT, n=244. Finding: Significantly decreased arterial stiffness and improved vascular elasticity.. PMID: 25694037.

## Evidence gaps

No direct evidence in hEDS, POTS, or MCAS populations. Mast cell evidence is historical (1975) and requires modern replication. No studies exist on heart rate or autonomic markers.

## Safety

**Side effects:** Excellent safety profile. Does not increase bleeding risk at standard doses.

**Interactions:** CONTRAINDICATED with warfarin/vitamin K antagonists. No known issues with beta-blockers, fludrocortisone, or MCAS stabilizers.

**Cautions:** Absolutely avoid if on warfarin. Coagulation safety confirmed at 90μg doses in healthy volunteers.

**Excipients to avoid:** Povidone, Sodium lauryl sulfate, PEG, Magnesium stearate

**Excipients that are safe:** HPMC capsules, Rice flour, Cellulose, Ascorbyl palmitate

## Frequently asked questions

### Why MK-7 instead of regular vitamin K?

Vitamin K comes in two main forms: K1 (phylloquinone) from leafy greens, primarily used for blood clotting, and K2 (menaquinone) from bacterial and animal sources, primarily used for calcium-directing proteins. K2 has several subforms (MK-4, MK-7, MK-9, etc.) defined by the length of their isoprenoid tails. MK-7 has the longest half-life and the strongest activation of osteocalcin and matrix Gla protein (the calcium-directing proteins). For maintenance dosing, MK-7 is the standard supplement choice.

### I'm on warfarin - can I take this?

No. This is the one absolute contraindication for K2 supplementation. Warfarin works by blocking vitamin K-dependent clotting factor activation; supplementing K2 directly opposes warfarin's mechanism and can destabilize INR control with serious clinical consequences. The same applies to other vitamin K antagonists. If you're on warfarin, skip vitamin K supplements entirely (take our formulation without the AM capsule, or talk to your prescriber about non-VKA alternatives like DOACs that don't have this conflict).

### Why not natto-derived MK-7?

Natto is the cheapest natural source of MK-7 and is what most commercial supplements use. The problem for our community: natto is heavily fermented and carries substantial biogenic amines (histamine, tyramine, polyamines) that ride along even into extracted MK-7 products. Synthetic and chickpea-fermented MK-7 produce the same molecule without that contamination profile, which is why we specify them.

### Does K2 actually help with mast cells?

Yes, with caveats. The supporting evidence is real but historical and understudied in MCAS specifically. K2 sits in the formulation as secondary mast cell support, not a primary stabilizer; the dedicated mast cell work happens through PEA, luteolin, quercetin, and astaxanthin. See the Addressing the Triad section above for the specific study references.

## References

[1] Kimura I et al.. (1975). Mast cell stabilization by menaquinone. PMID: 126001. https://pubmed.ncbi.nlm.nih.gov/126001/
[2] Abdel-Rahman MS. (2015). MK-7 in rheumatoid arthritis RCT decreases MMP-3. PMID: 26073022. https://pubmed.ncbi.nlm.nih.gov/26073022/
[3] Knapen MH et al.. (2015). 3-year MK-7 arterial stiffness trial. PMID: 25694037. https://pubmed.ncbi.nlm.nih.gov/25694037/
[4] Sato T et al.. (2012). MK-7 vs MK-4 bioavailability comparison. PMID: 23140417. https://pubmed.ncbi.nlm.nih.gov/23140417/
[5] Ren et al.. (2021). Coagulation safety with MK-7. PMID: 34115006. https://pubmed.ncbi.nlm.nih.gov/34115006/
[6] Kimura I et al.. PMID: 51576. https://pubmed.ncbi.nlm.nih.gov/51576/